As I step into Rajeev Juneja’s office at Mankind Pharma’s Delhi headquarters, the wall in front of me immediately commands attention. It features a collection of iconic quotes and striking ...

JPMorgan maintained its Overweight rating on Mankind Pharma Ltd (MANKIND:IN) and increased the price target from INR3,000.00 ...

Mankind Pharma's Q3 net profit was impacted by the $1.6 billion acquisition of Bharat Serums and Vaccines (BSV), which came into effect from October. Stocks to Watch Today: Indus Towers ...

India's Mankind Pharma reported a smaller-than-expected third-quarter profit on Thursday, hurt by a sharp rise in expenses.

Mankind Pharma Ltd on Wednesday said it has been imposed a GST related penalty of over Rs 2 crore by tax authority in Kolkata over alleged mismatch in figures for the period of FY18 to FY22.

The integration of BSV is on track, with focus on mandate brands, improving productivity and adopting best practices to ensure long term sustainable growth, Juneja stated.

10.03 for one tablet Mankind Pharma IPO: The issue, which is an offer for sale, is expected to fetch the pharma company's shareholders Rs 4,326.36 crore at the upper end of the price band of Rs ...

Earnings worries yank Indian shares to third week of losses January 24, 2025 India's Mankind Pharma reported a smaller-than-expected third-quarter profit on Thursday, hurt by a sharp rise in expenses.

Mankind Pharma Ltd on Wednesday said it has been imposed a GST related penalty of over Rs 2 crore by tax authority in Kolkata over alleged mismatch in figures for the period of FY18 to FY22.